Loading clinical trials...
Loading clinical trials...
A Dose Finding Study of CycloSam® (153-Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewing's Sarcoma, and Other Solid Tumor(s) to the Bone All Eligible)
Conditions
Interventions
153-Sm-DOTMP (Samarium-153-DOTMP)
Locations
4
United States
Clinical Trial Site
Chicago, Illinois, United States
Clinical Trial Site
Columbia, Missouri, United States
Clinical Trial Site
New Brunswick, New Jersey, United States
Clinical Trial Site
Houston, Texas, United States
Start Date
April 5, 2022
Primary Completion Date
April 5, 2024
Completion Date
November 1, 2024
Last Updated
August 23, 2023
NCT06898450
NCT05720117
NCT06658951
NCT05101070
NCT05098132
NCT05223608
Lead Sponsor
QSAM Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions